Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

Future Oncology

Volumn 14, Issue 11, 2018, Pages 1035-1047

  Richardson, Paul G ^a   Attal, Michel ^b   Campana, Frank ^c   Le Guennec, Solenn ^d   Hui, Ai Min ^c   Risse, Marie Laure ^d   Corzo, Kathryn ^c   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b La Croix du Sud Hospital   (France)

^c SANOFI   (United States)

^d SANOFI   (France)

Author keywords

CD38; immunomodulatory drugs; monoclonal antibody; multiple myeloma; progression free survival; protocol; trial in progress

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; ISATUXIMAB; PARACETAMOL; POMALIDOMIDE; RANITIDINE; DARATUMUMAB; MONOCLONAL ANTIBODY; THALIDOMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE;

EID: 85047212579     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0616     Document Type: Article

References (50)

1. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet 385(9983), 2197-2208 (2015).
2. Binder M, Rajkumar SV, Ketterling RP et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 6, e401 (2016).
3. Sonneveld P, Avet-Loiseau H, Lonial S et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood 127(24), 2955-2962 (2016).
4. Hari P. Recent advances in understanding multiple myeloma. Hematol. Oncol. Stem Cell Ther. doi:10.1016/j.hemonc.2017.05.005 (2017) (Epub ahead of print).
5. Eshaghian S, Berenson JR. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr. Opin. Support. Palliat. Care 6(3), 330-336 (2012).
6. Stewart AK, Rajkumar SV, Dimopoulos MA et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142-152 (2015).
7. Moreau P, Masszi T, Grzasko N et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374(17), 1621-1634 (2016).
8. San Miguel J, Weisel K, Moreau P et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, Phase III trial. Lancet Oncol. 14(11), 1055-1066 (2013).
9. Richardson PG, Siegel DS, Vij R et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized Phase II study. Blood 123(12), 1826-1832 (2014).
10. Morgan GJ, Davies FE, Gregory WM et al. Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial. Blood 119(23), 5374-5383 (2012).
11. Niesvizky R, Martin TG 3rd, Bensinger WI et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin. Cancer Res. 19(8), 2248-2256 (2013).
12. Jakubowiak AJ, Dytfeld D, Griffith KA et al. A Phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120(9), 1801-1809 (2012).
13. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679-686 (2010).
14. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24(1), 22-32 (2010).
15. Holstein SA, Mccarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 77(5), 505-520 (2017).
16. Dimopoulos MA, Swern AS, Li JS et al. Efficacy and safety of long-Term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 4, e257 (2014).
17. Palumbo A, Rajkumar SV, San Miguel JF et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J. Clin. Oncol. 32(6), 587-600 (2014).
18. Richardson PG, Weller E, Jagannath S et al. Multicenter, Phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J. Clin. Oncol. 27(34), 5713-5719 (2009).
19. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26(1), 149-157 (2012).
20. Laubach J, Garderet L, Mahindra A et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30(5), 1005-1017 (2016).
21. Lonial S, Dimopoulos M, Palumbo A et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621-631 (2015).
22. Deckert J, Wetzel MC, Bartle LM et al. SAR650984, a novel humanized CD38-Targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res. 20(17), 4574-4583 (2014).
23. Lonial S, Weiss BM, Usmani SZ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, Phase II trial. Lancet 387(10027), 1551-1560 (2016).
24. Lokhorst HM, Plesner T, Laubach JP et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373(13), 1207-1219 (2015).
25. Richardson PG, Jagannath S, Moreau P et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final Phase II results from the randomised, open-label, Phase Ib-II dose-escalation study. Lancet Haematol. 2(12), e516-e527 (2015).
26. Malavasi F, Deaglio S, Funaro A et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88(3), 841-886 (2008).
27. Chari A, Suvannasankha A, Fay JW et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 130(8), 974-981 (2017).
28. Jelinek T, Hajek R. Monoclonal antibodies-A new era in the treatment of multiple myeloma. Blood Rev. 30(2), 101-110 (2016).
29. Feng X, Zhang L, Acharya C et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23(15), 4290-4300 (2017).
30. Moreno L, Zabaleta A, Alignani D et al. Critical analysis on the mechanism of action (MoA) of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma (MM). Presented at: 58th ASH Annual Meeting & Exposition. CA, USA, 3-6 December 2016.
31. Martin T, Baz R, Benson DM et al. A Phase Ib study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129(25), 3294-3303 (2017).
32. Zhang B, Yang G, Dai S et al. SAR650984, a humanized anti-CD38 antibody potently modulates intracellular and extracellular nucleotide levels of cancer cells. Presented at: 105th Annual Meeting of the American Association for Cancer Research. CA, USA, 5-9 April 2014.
33. Wetzel M-C, Nicolazzi C, Vallée F et al. SAR650984: characterization of a potent Phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Presented at: American Association for Cancer Research 104th Annual Meeting. DC, USA, 6-10 April 2013.
34. Shen LS, Wang J, Shen DF et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin. Immunol. 131(1), 109-118 (2009).
35. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9(2), 606-612 (2003).
36. Jiang H, Acharya C, An G et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-Associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30(2), 399-408 (2016).
37. Martin TG, Hsu K, Strickland SA, Glenn MJ, Mikhael J, Charpentier E. A Phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. Presented at: American Society of Clinical Oncology 50th Annual Meeting. IL, USA, 30 May-3 June 2014.
38. Richter JR, Martin TG, Vij R et al. Updated data from a Phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). Presented at: The American Society of Clinical Oncology 52nd Annual Meeting. IL, USA, 3-7 June 2016.
39. Martin TG, Mannis GN, Chari A et al. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Presented at: American Society of Hematology 58th Annual Meeting & Exposition. CA, USA, 3-6 December 2016.
40. Mikhael J, Richardson PG, Usmani SZ et al. A Phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM). Presented at: American Society of Clinical Oncology 2017 Annual Meeting. IL, USA, 2-6 June 2017.
41. Richardson P, Mikhael J, Usmani S et al. Preliminary results from a Phase 1b study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma. Presented at: 16th International Myeloma Workshop 2017. New Delhi, India, 1-4 March 2017.
42. Richardson PG, Mikhael J, Usmani SZ et al. Preliminary results from a Phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Presented at: American Society of Hematology 58th Annual Meeting & Exposition. CA, USA, 3-6 December 2016.
43. Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17(8), e328-e346 (2016).
44. Usmani S, Ahmadi T, Ng Y et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist 21(ii), 1355-1361 (2016).
45. San Miguel JF, Weisel KC, Song KW et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized Phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica 100(10), 1334-1339 (2015).
46. Mikhael J, Richardson P, Usmani S et al. A Phase Ib study of isatuximab plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). Presented at: 22nd Congress of the European Hematology Association Madrid, Spain, 22-25 June 2017.
47. Vij R, Richardson PGG, Jagannath S et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). J. Clin. Oncol. 30(15 Suppl.), 8016 (2012).
48. Leleu X, Karlin L, Macro M et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood 125(9), 1411-1417 (2015).
49. Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319-1331 (2016).
50. Bhatnagar V, Gormley NJ, Luo L et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist 22(11), 1347-1353 (2017).